Cure8 research brief
Recognizing eye inflammation as a possible early sign of IBD could shorten diagnostic delays and lead to earlier gastroenterology evaluation and treatment, which is especially important for children who often wait years for diagnosis.
Ophthalmologists and eye-care clinicians, gastroenterologists, pediatricians, patients with recurrent non-infectious uveitis or scleritis, and parents/caregivers of affected children.
This review highlights that uveitis and scleritis can precede a diagnosis of IBD in a meaningful minority of patients and that diagnostic delays of years are common, especially in children.
The authors synthesized cohort studies, meta-analyses, and Mendelian randomization evidence and propose a practical, tiered screening framework for ophthalmology settings: Tier 1 universal GI-symptom screening for non-infectious/recurrent uveitis and all scleritis; Tier 2 targeted labs including fecal calprotectin for high-risk patients; Tier 3 low-threshold gastroenterology referral for positive screens or ongoing concern.
Pediatric patients warrant lower referral thresholds. This proposed framework is intended to complement clinical judgment and needs prospective validation before being adopted as standard practice.
This article is a review/abstract proposing a screening framework based on existing studies and genetic evidence; the framework has not yet been prospectively validated and should be used alongside clinical judgment. Mendelian randomization supports a causal link but does not establish screening effectiveness.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This paper evaluates CAR, a simple blood‑based biomarker, in children with IBD and finds it reflects disease severity and changes over time in pediatric Crohn’s disease. That matters because reliable, easy-to-measure...
Noninvasive stool markers that track endoscopic inflammation could reduce the need for frequent pediatric endoscopies, easing burden and risk for children with IBD. Strong correlation with endoscopy suggests these tests...
Fecal calprotectin measured by a point‑of‑care CGICA assay showed high accuracy for identifying colorectal inflammation and IBD in patients with chronic diarrhea, which could help avoid some unnecessary colonoscopies...
